Cordis US Corporation appears in FDA premarket approval records as the applicant for two PMA numbers covering the S.M.A.R.T. stent line. P020036, approved August 12, 2003, covers the S.M.A.R.T. Nitinol Stent System and S.M.A.R.T. Control Nitinol Stent System for an iliac indication. P120002, approved November 7, 2012, covers S.M.A.R.T. Control and S.M.A.R.T. Vascular Stent Systems, with the S.M.A.R.T. RADIANZ Vascular Stent System named in a later supplement title, for a superficial femoral artery indication. Both are Class 3 devices reviewed by the Cardiovascular advisory committee. [1][2][3][4]
Documented products and device technology
The records name nitinol vascular stent systems. P020036 lists generic name Stent, Iliac, product code NIO, and names the S.M.A.R.T. Nitinol Stent System and S.M.A.R.T. Control Nitinol Stent System. P120002 lists generic name Stent, Superficial Femoral Artery, product code NIP, and names S.M.A.R.T. Control and S.M.A.R.T. Vascular Stent Systems; the 2026 supplement title adds the S.M.A.R.T. RADIANZ Vascular Stent System. [1][2][3][4]
The FDA summaries of safety and effectiveness data for both PMAs identify the device trade names and generic names consistently with the approval records, and describe the applicant as Cordis Corporation at 14201 NW 60th Avenue, Miami Lakes, FL 33014. That address appears as a filing address in FDA records, not as a verified corporate headquarters. [6][7][9]
Dated filing examples
Two 30-Day Notices were decided October 15, 2026, both received September 15, 2026. P020036/S061 covers an alternate supplier of a Bismuth Sub Carbonate Blend used in the catheter outer member for the S.M.A.R.T. Control Nitinol Stent System. P120002/S036 covers the same supplier change for the S.M.A.R.T. and S.M.A.R.T. Control Vascular Stent Systems and the S.M.A.R.T. RADIANZ Vascular Stent System. Both carry supplement reason Process Change - Manufacturer/Sterilizer/Packager/Supplier. [1][2]
The original approvals are older: P020036 was received September 5, 2002 and approved August 12, 2003, with docket 03M-0381; P120002 was received February 3, 2012 and approved November 7, 2012, with docket 12M-1183. Neither original record carries an expedited review flag. [3][4]
Applicant identity and scope limits
The FDA summaries for P120002 name the applicant as Cordis Corporation, a Johnson & Johnson Company. The PMA records themselves list Cordis US Corporation as applicant. The relationship between these names is documented only to the extent the filings state it; no current ownership, parent structure or brand arrangement beyond those statements is verified here. [2][6][9]
The linked collection holds four PMA records as of the snapshot date, with decision counts of two approvals and two 30-Day Notices; the smaller record sample shows the same split. These are counts of the filings retrieved, not measures of total portfolio, sales or safety performance. No recall records appear in the retrieved sample. [1][2][3][4]
What the filings do and do not establish
The approval statements describe intended use for improving luminal diameter in specified peripheral arterial anatomy, and the summaries point readers to device labeling for indications, contraindications, warnings, precautions and adverse events. The records do not provide clinical outcome figures, commercial availability or post-market performance data. [3][4][6][7]
Manufacturing compliance statements appear in the summaries: the P020036 summary states FDA inspections found the applicant's facilities in compliance with the Quality System Regulation, and the P120002 summary states the manufacturing facility was found in compliance with the Quality System regulation at 21 CFR 820. These are statements about inspections at the time of approval. [7][9]
